Back to Search
Start Over
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
- Source :
-
European Journal of Nuclear Medicine & Molecular Imaging . Jun2017, Vol. 44 Issue 6, p1099-1100. 2p. 1 Black and White Photograph. - Publication Year :
- 2017
-
Abstract
- The article offers information on use of the prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA as a safe treatment option in patients with metastasized castration-resistant prostate cancer (mCRPC) with appropriate selection, with reference to a case study of a patient.
Details
- Language :
- English
- ISSN :
- 16197070
- Volume :
- 44
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- European Journal of Nuclear Medicine & Molecular Imaging
- Publication Type :
- Academic Journal
- Accession number :
- 122598626
- Full Text :
- https://doi.org/10.1007/s00259-017-3657-9